Psychometric characteristics of the MATRICS Consensus Cognitive Battery in a large pooled cohort of stable schizophrenia patients
The MATRICS Consensus Cognitive Battery (MCCB) was developed to assess cognitive treatment effects in schizophrenia clinical trials, and is considered the FDA gold standard outcome measure for that purpose. The aim of the present study was to establish pre-treatment psychometric characteristics of t...
Saved in:
Published in | Schizophrenia research Vol. 190; pp. 172 - 179 |
---|---|
Main Authors | , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Netherlands
Elsevier B.V
01.12.2017
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | The MATRICS Consensus Cognitive Battery (MCCB) was developed to assess cognitive treatment effects in schizophrenia clinical trials, and is considered the FDA gold standard outcome measure for that purpose. The aim of the present study was to establish pre-treatment psychometric characteristics of the MCCB in a large pooled sample. The dataset included 2616 stable schizophrenia patients enrolled in 15 different clinical trials between 2007 and 2016 within the United States (94%) and Canada (6%). The MCCB was administered twice prior to the initiation of treatment in 1908 patients. Test-retest reliability and practice effects of the cognitive composite score, the neurocognitive composite score, which excludes the domain Social Cognition, and the subtests/domains were examined using Intra-Class Correlations (ICC) and Cohen's d. Simulated regression models explored which domains explained the greatest portion of variance in composite scores. Test-retest reliability was high (ICC=0.88) for both composite scores. Practice effects were small for the cognitive (d=0.15) and neurocognitive (d=0.17) composites. Simulated bootstrap regression analyses revealed that 3 of the 7 domains explained 86% of the variance for both composite scores. The domains that entered most frequently in the top 3 positions of the regression models were Speed of Processing, Working Memory, and Visual Learning. Findings provide definitive psychometric characteristics and a benchmark comparison for clinical trials using the MCCB. The test-retest reliability of the MCCB composite scores is considered excellent and the learning effects are small, fulfilling two of the key criteria for outcome measures in cognition clinical trials. |
---|---|
AbstractList | The MATRICS Consensus Cognitive Battery (MCCB) was developed to assess cognitive treatment effects in schizophrenia clinical trials, and is considered the FDA gold standard outcome measure for that purpose. The aim of the present study was to establish pre-treatment psychometric characteristics of the MCCB in a large pooled sample. The dataset included 2616 stable schizophrenia patients enrolled in 15 different clinical trials between 2007 and 2016 within the United States (94%) and Canada (6%). The MCCB was administered twice prior to the initiation of treatment in 1908 patients. Test-retest reliability and practice effects of the cognitive composite score, the neurocognitive composite score, which excludes the domain Social Cognition, and the subtests/domains were examined using Intra-Class Correlations (ICC) and Cohen's d. Simulated regression models explored which domains explained the greatest portion of variance in composite scores. Test-retest reliability was high (ICC=0.88) for both composite scores. Practice effects were small for the cognitive (d=0.15) and neurocognitive (d=0.17) composites. Simulated bootstrap regression analyses revealed that 3 of the 7 domains explained 86% of the variance for both composite scores. The domains that entered most frequently in the top 3 positions of the regression models were Speed of Processing, Working Memory, and Visual Learning. Findings provide definitive psychometric characteristics and a benchmark comparison for clinical trials using the MCCB. The test-retest reliability of the MCCB composite scores is considered excellent and the learning effects are small, fulfilling two of the key criteria for outcome measures in cognition clinical trials.The MATRICS Consensus Cognitive Battery (MCCB) was developed to assess cognitive treatment effects in schizophrenia clinical trials, and is considered the FDA gold standard outcome measure for that purpose. The aim of the present study was to establish pre-treatment psychometric characteristics of the MCCB in a large pooled sample. The dataset included 2616 stable schizophrenia patients enrolled in 15 different clinical trials between 2007 and 2016 within the United States (94%) and Canada (6%). The MCCB was administered twice prior to the initiation of treatment in 1908 patients. Test-retest reliability and practice effects of the cognitive composite score, the neurocognitive composite score, which excludes the domain Social Cognition, and the subtests/domains were examined using Intra-Class Correlations (ICC) and Cohen's d. Simulated regression models explored which domains explained the greatest portion of variance in composite scores. Test-retest reliability was high (ICC=0.88) for both composite scores. Practice effects were small for the cognitive (d=0.15) and neurocognitive (d=0.17) composites. Simulated bootstrap regression analyses revealed that 3 of the 7 domains explained 86% of the variance for both composite scores. The domains that entered most frequently in the top 3 positions of the regression models were Speed of Processing, Working Memory, and Visual Learning. Findings provide definitive psychometric characteristics and a benchmark comparison for clinical trials using the MCCB. The test-retest reliability of the MCCB composite scores is considered excellent and the learning effects are small, fulfilling two of the key criteria for outcome measures in cognition clinical trials. The MATRICS Consensus Cognitive Battery (MCCB) was developed to assess cognitive treatment effects in schizophrenia clinical trials, and is considered the FDA gold standard outcome measure for that purpose. The aim of the present study was to establish pre-treatment psychometric characteristics of the MCCB in a large pooled sample. The dataset included 2616 stable schizophrenia patients enrolled in 15 different clinical trials between 2007 and 2016 within the United States (94%) and Canada (6%). The MCCB was administered twice prior to the initiation of treatment in 1908 patients. Test-retest reliability and practice effects of the cognitive composite score, the neurocognitive composite score, which excludes the domain Social Cognition, and the subtests/domains were examined using Intra-Class Correlations (ICC) and Cohen's d. Simulated regression models explored which domains explained the greatest portion of variance in composite scores. Test-retest reliability was high (ICC=0.88) for both composite scores. Practice effects were small for the cognitive (d=0.15) and neurocognitive (d=0.17) composites. Simulated bootstrap regression analyses revealed that 3 of the 7 domains explained 86% of the variance for both composite scores. The domains that entered most frequently in the top 3 positions of the regression models were Speed of Processing, Working Memory, and Visual Learning. Findings provide definitive psychometric characteristics and a benchmark comparison for clinical trials using the MCCB. The test-retest reliability of the MCCB composite scores is considered excellent and the learning effects are small, fulfilling two of the key criteria for outcome measures in cognition clinical trials. Abstract The MATRICS Consensus Cognitive Battery (MCCB) was developed to assess cognitive treatment effects in schizophrenia clinical trials, and is considered the FDA gold standard outcome measure for that purpose. The aim of the present study was to establish pre-treatment psychometric characteristics of the MCCB in a large pooled sample. The dataset included 2616 stable schizophrenia patients enrolled in 15 different clinical trials between 2007 and 2016 within the United States (94%) and Canada (6%). The MCCB was administered twice prior to the initiation of treatment in 1908 patients. Test-retest reliability and practice effects of the cognitive composite score, the neurocognitive composite score, which excludes the domain Social Cognition, and the subtests/domains were examined using Intra-Class Correlations (ICC) and Cohen's d . Simulated regression models explored which domains explained the greatest portion of variance in composite scores. Test-retest reliability was high (ICC = 0.88) for both composite scores. Practice effects were small for the cognitive ( d = 0.15) and neurocognitive ( d = 0.17) composites. Simulated bootstrap regression analyses revealed that 3 of the 7 domains explained 86% of the variance for both composite scores. The domains that entered most frequently in the top 3 positions of the regression models were Speed of Processing, Working Memory, and Visual Learning. Findings provide definitive psychometric characteristics and a benchmark comparison for clinical trials using the MCCB. The test-retest reliability of the MCCB composite scores is considered excellent and the learning effects are small, fulfilling two of the key criteria for outcome measures in cognition clinical trials. |
Author | Georgiades, Anastasia Umbricht, Daniel Keefe, Richard S.E. Loebel, Antony Davis, Vicki G. Hilt, Dana C. Walker, Trina W. Khan, Anzalee Haig, George Atkins, Alexandra S. Sand, Michael Dunayevich, Eduardo |
Author_xml | – sequence: 1 givenname: Anastasia surname: Georgiades fullname: Georgiades, Anastasia organization: NeuroCog Trials, Durham, NC, USA – sequence: 2 givenname: Vicki G. surname: Davis fullname: Davis, Vicki G. organization: NeuroCog Trials, Durham, NC, USA – sequence: 3 givenname: Alexandra S. surname: Atkins fullname: Atkins, Alexandra S. organization: NeuroCog Trials, Durham, NC, USA – sequence: 4 givenname: Anzalee surname: Khan fullname: Khan, Anzalee organization: NeuroCog Trials, Durham, NC, USA – sequence: 5 givenname: Trina W. surname: Walker fullname: Walker, Trina W. organization: NeuroCog Trials, Durham, NC, USA – sequence: 6 givenname: Antony surname: Loebel fullname: Loebel, Antony organization: Sunovion Pharmaceuticals Inc, USA – sequence: 7 givenname: George surname: Haig fullname: Haig, George organization: Abbvie, USA – sequence: 8 givenname: Dana C. surname: Hilt fullname: Hilt, Dana C. organization: FORUM pharma, USA – sequence: 9 givenname: Eduardo surname: Dunayevich fullname: Dunayevich, Eduardo organization: Takeda, USA – sequence: 10 givenname: Daniel surname: Umbricht fullname: Umbricht, Daniel organization: F. Hoffmann-La Roche Ltd, USA – sequence: 11 givenname: Michael surname: Sand fullname: Sand, Michael organization: Boehringer-Ingelheim, USA – sequence: 12 givenname: Richard S.E. orcidid: 0000-0002-0173-8897 surname: Keefe fullname: Keefe, Richard S.E. email: richard.keefe@duke.edu organization: NeuroCog Trials, Durham, NC, USA |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/28433500$$D View this record in MEDLINE/PubMed |
BookMark | eNqVkktv1DAUhS1URKeFf4CQl2wSrmPnhRBSGfGoVASiZW05zk3jIWOntqfSsOOf4zCFBRKqWPkuvnN8dc49IUfWWSTkKYOcAatebPKgR48hL4DVOfAcBDwgK1bWPCtKaI_ICtoCsratxDE5CWEDAKyE-hE5LhrBeQmwIj8-h70e3RajN5rqUXmlI3oTotGBuoHGEenHs6sv5-tLunY2oA27kKZra6K5RfpGxcTvqbFU0Un5a6SzcxP2VLvR-bh4hKi6CWna13x3c1raGkVnFQ3aGB6Th4OaAj65e0_J13dvr9YfsotP78_XZxeZFjXErOlqLupCDG2LhYCSqW5QVS0UVp1iDWO17nUPYmBMlaIa-KA4V0XXV6wZkNf8lDw_-M7e3ewwRLk1QeM0KYtuFyRrWiZK0UKb0Gd36K7bYi9nb7bK7-Xv2BIgDoD2LgSPwx-EgVzakRt5aEcu7UjgMrWTZC__kmkTUwzORq_MdJ_49UGMKaRbgz5BKUCNvfGoo-yd-V8DPRlrtJq-4R7Dxu28TQVIJkMhQV4u17McD6s5sOZXLK_-bXD__z8BX_TYWw |
CitedBy_id | crossref_primary_10_30773_pi_2020_0306 crossref_primary_10_1093_arclin_acaa004 crossref_primary_10_1192_j_eurpsy_2022_2316 crossref_primary_10_3389_fpsyt_2018_00356 crossref_primary_10_1016_j_scog_2019_01_001 crossref_primary_10_1016_j_scog_2022_100270 crossref_primary_10_1177_20451253241302603 crossref_primary_10_3389_fpsyt_2019_00648 crossref_primary_10_1177_0269881119855302 crossref_primary_10_1016_j_scog_2019_100171 crossref_primary_10_1016_S2215_0366_20_30513_7 crossref_primary_10_1038_s41398_023_02593_1 crossref_primary_10_1093_schbul_sbac065 crossref_primary_10_1002_hbm_24976 crossref_primary_10_4103_indianjpsychiatry_indianjpsychiatry_690_24 crossref_primary_10_1016_j_jpsychires_2022_10_069 crossref_primary_10_1016_j_jpsychires_2024_03_014 crossref_primary_10_3389_fnhum_2021_777043 crossref_primary_10_1080_13854046_2021_1962410 crossref_primary_10_1016_j_heliyon_2024_e25915 crossref_primary_10_1016_j_schres_2017_05_009 crossref_primary_10_1016_j_psychres_2024_116121 crossref_primary_10_1016_j_psychres_2022_114479 crossref_primary_10_1016_j_schres_2020_11_018 crossref_primary_10_1093_schbul_sbae051 crossref_primary_10_1093_schbul_sbae151 crossref_primary_10_1177_02698811211000778 crossref_primary_10_1093_schbul_sby049 crossref_primary_10_1016_j_scog_2024_100310 crossref_primary_10_1016_j_schres_2024_04_007 crossref_primary_10_1038_s41398_022_02254_9 crossref_primary_10_1186_s12888_019_2018_6 crossref_primary_10_1016_j_schres_2020_08_008 crossref_primary_10_1093_schbul_sbae191 crossref_primary_10_1016_j_bpsc_2018_06_008 crossref_primary_10_1007_s00406_020_01200_4 |
Cites_doi | 10.1016/S0920-9964(02)00425-5 10.1176/appi.ajp.2014.14070936 10.1016/j.biopsych.2010.09.052 10.1016/j.jagp.2012.10.011 10.1176/appi.ajp.2008.07071135 10.1001/archpsyc.58.1.24 10.1093/oxfordjournals.schbul.a033430 10.1615/CritRevNeurobiol.v14.i1.10 10.1016/j.schres.2004.09.004 10.1176/appi.ajp.2007.07010042 10.1037/0033-2909.133.5.833 10.1016/j.schres.2011.11.026 10.1037/0021-9010.92.2.373 10.1016/j.biopsych.2005.01.003 10.1093/schbul/sbn037 10.1016/j.biopsych.2004.06.023 10.1016/j.schres.2011.11.001 10.1017/S1355617703930074 10.1037/0894-4105.12.3.426 10.1016/j.schres.2010.09.015 10.1176/appi.ajp.2007.07010043 10.1038/npp.2008.200 10.1037/a0019026 |
ContentType | Journal Article |
Copyright | 2017 Elsevier B.V. Elsevier B.V. Copyright © 2017 Elsevier B.V. All rights reserved. |
Copyright_xml | – notice: 2017 Elsevier B.V. – notice: Elsevier B.V. – notice: Copyright © 2017 Elsevier B.V. All rights reserved. |
DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 |
DOI | 10.1016/j.schres.2017.03.040 |
DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
DatabaseTitleList | MEDLINE - Academic MEDLINE |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
EISSN | 1573-2509 |
EndPage | 179 |
ExternalDocumentID | 28433500 10_1016_j_schres_2017_03_040 S0920996417301809 1_s2_0_S0920996417301809 |
Genre | Clinical Trial Research Support, Non-U.S. Gov't Journal Article Research Support, N.I.H., Extramural |
GrantInformation_xml | – fundername: NIMH NIH HHS grantid: N01 MH90001 |
GroupedDBID | --- --K --M -~X .1- .FO .GJ .~1 0R~ 123 1B1 1P~ 1RT 1~. 1~5 4.4 457 4G. 4H- 53G 5VS 7-5 71M 8P~ 9JM 9JO AABNK AADFP AAEDT AAEDW AAGJA AAGUQ AAIKJ AAKOC AALRI AAOAW AAQFI AAQXK AATTM AAWTL AAXKI AAXLA AAXUO AAYWO ABBQC ABCQJ ABFNM ABIVO ABJNI ABMAC ABMZM ABOYX ABWVN ABXDB ACDAQ ACGFS ACHQT ACIEU ACIUM ACRLP ACRPL ACVFH ACXNI ADBBV ADCNI ADEZE ADMUD ADNMO AEBSH AEIPS AEKER AENEX AEUPX AEVXI AFJKZ AFPUW AFRHN AFTJW AFXIZ AGCQF AGHFR AGQPQ AGUBO AGWIK AGYEJ AHHHB AIEXJ AIGII AIIUN AIKHN AITUG AJRQY AJUYK AKBMS AKRWK AKYEP ALMA_UNASSIGNED_HOLDINGS AMRAJ ANKPU ANZVX APXCP ASPBG AVWKF AXJTR AZFZN BKOJK BLXMC BNPGV CS3 DU5 EBS EFJIC EFKBS EJD EO8 EO9 EP2 EP3 F5P FDB FEDTE FGOYB FIRID FNPLU FYGXN G-2 G-Q GBLVA HEG HMK HMO HMQ HMW HVGLF HZ~ IHE J1W KOM M29 M2V M39 M3V M41 MO0 MOBAO N9A O-L O9- OAUVE OH0 OKEIE OU- OZT P-8 P-9 P2P PC. Q38 R2- ROL RPZ SAE SCC SDF SDG SDP SEL SES SEW SNS SPCBC SPS SSB SSH SSN SSY SSZ T5K WUQ Z5R ~G- AACTN AFCTW AFKWA AJOXV AMFUW RIG AADPK AAIAV ABLVK ABYKQ AFYLN AJBFU EFLBG LCYCR AAYXX AGRNS CITATION CGR CUY CVF ECM EIF NPM 7X8 |
ID | FETCH-LOGICAL-c470t-8b734724f99e24051abfa674ae6ba18117cdcd04f11a546f3fa33a2bd618fe373 |
IEDL.DBID | .~1 |
ISSN | 0920-9964 1573-2509 |
IngestDate | Fri Jul 11 12:26:36 EDT 2025 Wed Feb 19 02:42:37 EST 2025 Thu Apr 24 22:59:30 EDT 2025 Tue Jul 01 04:00:54 EDT 2025 Fri Feb 23 02:32:19 EST 2024 Sun Feb 23 10:19:46 EST 2025 Tue Aug 26 19:42:06 EDT 2025 |
IsPeerReviewed | true |
IsScholarly | true |
Keywords | Schizophrenia MATRICS Consensus Cognitive Battery Cognition |
Language | English |
License | Copyright © 2017 Elsevier B.V. All rights reserved. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c470t-8b734724f99e24051abfa674ae6ba18117cdcd04f11a546f3fa33a2bd618fe373 |
Notes | ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-1 content type line 23 |
ORCID | 0000-0002-0173-8897 |
PMID | 28433500 |
PQID | 1891454909 |
PQPubID | 23479 |
PageCount | 8 |
ParticipantIDs | proquest_miscellaneous_1891454909 pubmed_primary_28433500 crossref_primary_10_1016_j_schres_2017_03_040 crossref_citationtrail_10_1016_j_schres_2017_03_040 elsevier_sciencedirect_doi_10_1016_j_schres_2017_03_040 elsevier_clinicalkeyesjournals_1_s2_0_S0920996417301809 elsevier_clinicalkey_doi_10_1016_j_schres_2017_03_040 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 2017-12-01 |
PublicationDateYYYYMMDD | 2017-12-01 |
PublicationDate_xml | – month: 12 year: 2017 text: 2017-12-01 day: 01 |
PublicationDecade | 2010 |
PublicationPlace | Netherlands |
PublicationPlace_xml | – name: Netherlands |
PublicationTitle | Schizophrenia research |
PublicationTitleAlternate | Schizophr Res |
PublicationYear | 2017 |
Publisher | Elsevier B.V |
Publisher_xml | – name: Elsevier B.V |
References | Collie, Maruff, Darby, McStephen (bb0025) 2003; 9 Javitt, Buchanan, Keefe, Kern, McMahon, Green, Lieberman, Goff, Csernansky, McEvoy, Jarskog, Seidman, Gold, Kimhy, Nolan, Barch, Ball, Robinson, Marder (bb0070) 2012; 136 Rajji, Voineskos, Butters, Miranda, Arenovich, Menon, Ismail, Kern, Mulsant (bb0105) 2013; 21 Keefe, Eesley, Poe (bb0075) 2005; 57 Green, Harris, Nuechterlein (bb0050) 2014; 171 Rodriguez-Jimenez, Bagney, Garcia-Navarro, Aparicio, Lopez-Anton, Moreno-Ortega, Jimenez-Arriero, Santos, Lobo, Kern, Green, Nuechterlein, Palomo (bb0115) 2012; 134 Buchanan, Keefe, Lieberman, Barch, Csernansky, Goff, Gold, Green, Jarskog, Javitt, Kimhy, Kraus, McEvoy, Mesholam-Gately, Seidman, Ball, McMahon, Kern, Robinson, Marder (bb0015) 2011; 69 Nuechterlein, Green, Kern, Baade, Barch, Cohen, Essock, Fenton, Frese, Gold, Goldberg, Heaton, Keefe, Kraemer, Mesholam-Gately, Seidman, Stover, Weinberger, Young, Zalcman, Marder (bb0100) 2008; 165 Barch, Carter, Committee (bb0005) 2008; 34 Heinrichs, Zakzanis (bb0065) 1998; 12 Hausknecht, Halpert, Di Paolo, Moriarty Gerrard (bb0055) 2007; 92 Freedman, Olincy, Buchanan, Harris, Gold, Johnson, Allensworth, Guzman-Bonilla, Clement, Ball, Kutnick, Pender, Martin, Stevens, Wagner, Zerbe, Soti, Kem (bb0035) 2008; 165 Keefe, Fox, Harvey, Cucchiaro, Siu, Loebel (bb0080) 2011; 125 Cohen (bb0020) 1977 Green, Kern, Braff, Mintz (bb0040) 2000; 26 Lieberman, Papadakis, Csernansky, Litman, Volavka, Jia, Gage, Group, M.-M.-S (bb0095) 2009; 34 Salthouse (bb0120) 2010; 24 Kern, Green, Nuechterlein, Deng (bb0085) 2004; 72 Kern, Nuechterlein, Green, Baade, Fenton, Gold, Keefe, Mesholam-Gately, Mintz, Seidman, Stover, Marder (bb0090) 2008; 165 Heaton, Gladsjo, Palmer, Kuck, Marcotte, Jeste (bb0060) 2001; 58 Beglinger, Ahmed, Derby, Siemers, Fastenau, Crawford-Miller, Shekhar, Kareken (bb0010) 2003; 62 Elvevag, Goldberg (bb0030) 2000; 14 Green, Nuechterlein, Gold, Barch, Cohen, Essock, Fenton, Frese, Goldberg, Heaton, Keefe, Kern, Kraemer, Stover, Weinberger, Zalcman, Marder (bb0045) 2004; 56 Reichenberg, Harvey (bb0110) 2007; 133 Kern (10.1016/j.schres.2017.03.040_bb0085) 2004; 72 Cohen (10.1016/j.schres.2017.03.040_bb0020) 1977 Collie (10.1016/j.schres.2017.03.040_bb0025) 2003; 9 Elvevag (10.1016/j.schres.2017.03.040_bb0030) 2000; 14 Hausknecht (10.1016/j.schres.2017.03.040_bb0055) 2007; 92 Javitt (10.1016/j.schres.2017.03.040_bb0070) 2012; 136 Salthouse (10.1016/j.schres.2017.03.040_bb0120) 2010; 24 Freedman (10.1016/j.schres.2017.03.040_bb0035) 2008; 165 Nuechterlein (10.1016/j.schres.2017.03.040_bb0100) 2008; 165 Buchanan (10.1016/j.schres.2017.03.040_bb0015) 2011; 69 Heinrichs (10.1016/j.schres.2017.03.040_bb0065) 1998; 12 Green (10.1016/j.schres.2017.03.040_bb0040) 2000; 26 Beglinger (10.1016/j.schres.2017.03.040_bb0010) 2003; 62 Rajji (10.1016/j.schres.2017.03.040_bb0105) 2013; 21 Barch (10.1016/j.schres.2017.03.040_bb0005) 2008; 34 Rodriguez-Jimenez (10.1016/j.schres.2017.03.040_bb0115) 2012; 134 Keefe (10.1016/j.schres.2017.03.040_bb0075) 2005; 57 Kern (10.1016/j.schres.2017.03.040_bb0090) 2008; 165 Heaton (10.1016/j.schres.2017.03.040_bb0060) 2001; 58 Green (10.1016/j.schres.2017.03.040_bb0050) 2014; 171 Keefe (10.1016/j.schres.2017.03.040_bb0080) 2011; 125 Lieberman (10.1016/j.schres.2017.03.040_bb0095) 2009; 34 Green (10.1016/j.schres.2017.03.040_bb0045) 2004; 56 Reichenberg (10.1016/j.schres.2017.03.040_bb0110) 2007; 133 |
References_xml | – volume: 171 start-page: 1151 year: 2014 end-page: 1154 ident: bb0050 article-title: The MATRICS consensus cognitive battery: what we know 6 publication-title: Am. J. Psychiatry – volume: 58 start-page: 24 year: 2001 end-page: 32 ident: bb0060 article-title: Stability and course of neuropsychological deficits in schizophrenia publication-title: Arch. Gen. Psychiatry – volume: 165 start-page: 203 year: 2008 end-page: 213 ident: bb0100 article-title: The MATRICS Consensus Cognitive Battery, part 1: test selection, reliability, and validity publication-title: Am. J. Psychiatry – volume: 72 start-page: 11 year: 2004 end-page: 19 ident: bb0085 article-title: NIMH-MATRICS survey on assessment of neurocognition in schizophrenia publication-title: Schizophr. Res. – volume: 21 start-page: 108 year: 2013 end-page: 118 ident: bb0105 article-title: Cognitive performance of individuals with schizophrenia across seven decades: a study using the MATRICS Consensus Cognitive Battery publication-title: Am. J. Geriatr. Psychiatry – year: 1977 ident: bb0020 article-title: Statistical Power Analysis for the Behavioral Sciences – volume: 125 start-page: 161 year: 2011 end-page: 168 ident: bb0080 article-title: Characteristics of the MATRICS Consensus Cognitive Battery in a 29-site antipsychotic schizophrenia clinical trial publication-title: Schizophr. Res. – volume: 92 start-page: 373 year: 2007 end-page: 385 ident: bb0055 article-title: Retesting in selection: a meta-analysis of coaching and practice effects for tests of cognitive ability publication-title: J. Appl. Psychol. – volume: 62 start-page: 191 year: 2003 end-page: 194 ident: bb0010 article-title: Neuropsychological practice effects and change detection in people with schizophrenia publication-title: Schizophr. Res. – volume: 34 start-page: 1322 year: 2009 end-page: 1329 ident: bb0095 article-title: A randomized, placebo-controlled study of memantine as adjunctive treatment in patients with schizophrenia publication-title: Neuropsychopharmacology – volume: 133 start-page: 833 year: 2007 end-page: 858 ident: bb0110 article-title: Neuropsychological impairments in schizophrenia: integration of performance-based and brain imaging findings publication-title: Psychol. Bull. – volume: 26 start-page: 119 year: 2000 end-page: 136 ident: bb0040 article-title: Neurocognitive deficits and functional outcome in schizophrenia: are we measuring the “right stuff”? publication-title: Schizophr. Bull. – volume: 165 start-page: 214 year: 2008 end-page: 220 ident: bb0090 article-title: The MATRICS Consensus Cognitive Battery, part 2: co-norming and standardization publication-title: Am. J. Psychiatry – volume: 14 start-page: 1 year: 2000 end-page: 21 ident: bb0030 article-title: Cognitive impairment in schizophrenia is the core of the disorder publication-title: Crit. Rev. Neurobiol. – volume: 57 start-page: 688 year: 2005 end-page: 691 ident: bb0075 article-title: Defining a cognitive function decrement in schizophrenia publication-title: Biol. Psychiatry – volume: 134 start-page: 279 year: 2012 end-page: 284 ident: bb0115 article-title: The MATRICS Consensus Cognitive Battery (MCCB): co-norming and standardization in Spain publication-title: Schizophr. Res. – volume: 136 start-page: 25 year: 2012 end-page: 31 ident: bb0070 article-title: Effect of the neuroprotective peptide davunetide (AL-108) on cognition and functional capacity in schizophrenia publication-title: Schizophr. Res. – volume: 34 start-page: 613 year: 2008 end-page: 618 ident: bb0005 article-title: Measurement issues in the use of cognitive neuroscience tasks in drug development for impaired cognition in schizophrenia: a report of the second consensus building conference of the CNTRICS initiative publication-title: Schizophr. Bull. – volume: 24 start-page: 563 year: 2010 end-page: 572 ident: bb0120 article-title: Influence of age on practice effects in longitudinal neurocognitive change publication-title: Neuropsychology – volume: 12 start-page: 426 year: 1998 end-page: 445 ident: bb0065 article-title: Neurocognitive deficit in schizophrenia: a quantitative review of the evidence publication-title: Neuropsychology – volume: 69 start-page: 442 year: 2011 end-page: 449 ident: bb0015 article-title: A randomized clinical trial of MK-0777 for the treatment of cognitive impairments in people with schizophrenia publication-title: Biol. Psychiatry – volume: 165 start-page: 1040 year: 2008 end-page: 1047 ident: bb0035 article-title: Initial phase 2 trial of a nicotinic agonist in schizophrenia publication-title: Am. J. Psychiatry – volume: 9 start-page: 419 year: 2003 end-page: 428 ident: bb0025 article-title: The effects of practice on the cognitive test performance of neurologically normal individuals assessed at brief test-retest intervals publication-title: J. Int. Neuropsychol. Soc. – volume: 56 start-page: 301 year: 2004 end-page: 307 ident: bb0045 article-title: Approaching a consensus cognitive battery for clinical trials in schizophrenia: the NIMH-MATRICS conference to select cognitive domains and test criteria publication-title: Biol. Psychiatry – volume: 62 start-page: 191 issue: 1–2 year: 2003 ident: 10.1016/j.schres.2017.03.040_bb0010 article-title: Neuropsychological practice effects and change detection in people with schizophrenia publication-title: Schizophr. Res. doi: 10.1016/S0920-9964(02)00425-5 – volume: 171 start-page: 1151 issue: 11 year: 2014 ident: 10.1016/j.schres.2017.03.040_bb0050 article-title: The MATRICS consensus cognitive battery: what we know 6years later publication-title: Am. J. Psychiatry doi: 10.1176/appi.ajp.2014.14070936 – volume: 69 start-page: 442 issue: 5 year: 2011 ident: 10.1016/j.schres.2017.03.040_bb0015 article-title: A randomized clinical trial of MK-0777 for the treatment of cognitive impairments in people with schizophrenia publication-title: Biol. Psychiatry doi: 10.1016/j.biopsych.2010.09.052 – volume: 21 start-page: 108 issue: 2 year: 2013 ident: 10.1016/j.schres.2017.03.040_bb0105 article-title: Cognitive performance of individuals with schizophrenia across seven decades: a study using the MATRICS Consensus Cognitive Battery publication-title: Am. J. Geriatr. Psychiatry doi: 10.1016/j.jagp.2012.10.011 – volume: 165 start-page: 1040 issue: 8 year: 2008 ident: 10.1016/j.schres.2017.03.040_bb0035 article-title: Initial phase 2 trial of a nicotinic agonist in schizophrenia publication-title: Am. J. Psychiatry doi: 10.1176/appi.ajp.2008.07071135 – volume: 58 start-page: 24 issue: 1 year: 2001 ident: 10.1016/j.schres.2017.03.040_bb0060 article-title: Stability and course of neuropsychological deficits in schizophrenia publication-title: Arch. Gen. Psychiatry doi: 10.1001/archpsyc.58.1.24 – volume: 26 start-page: 119 issue: 1 year: 2000 ident: 10.1016/j.schres.2017.03.040_bb0040 article-title: Neurocognitive deficits and functional outcome in schizophrenia: are we measuring the “right stuff”? publication-title: Schizophr. Bull. doi: 10.1093/oxfordjournals.schbul.a033430 – volume: 14 start-page: 1 issue: 1 year: 2000 ident: 10.1016/j.schres.2017.03.040_bb0030 article-title: Cognitive impairment in schizophrenia is the core of the disorder publication-title: Crit. Rev. Neurobiol. doi: 10.1615/CritRevNeurobiol.v14.i1.10 – volume: 72 start-page: 11 issue: 1 year: 2004 ident: 10.1016/j.schres.2017.03.040_bb0085 article-title: NIMH-MATRICS survey on assessment of neurocognition in schizophrenia publication-title: Schizophr. Res. doi: 10.1016/j.schres.2004.09.004 – year: 1977 ident: 10.1016/j.schres.2017.03.040_bb0020 – volume: 165 start-page: 203 issue: 2 year: 2008 ident: 10.1016/j.schres.2017.03.040_bb0100 article-title: The MATRICS Consensus Cognitive Battery, part 1: test selection, reliability, and validity publication-title: Am. J. Psychiatry doi: 10.1176/appi.ajp.2007.07010042 – volume: 133 start-page: 833 issue: 5 year: 2007 ident: 10.1016/j.schres.2017.03.040_bb0110 article-title: Neuropsychological impairments in schizophrenia: integration of performance-based and brain imaging findings publication-title: Psychol. Bull. doi: 10.1037/0033-2909.133.5.833 – volume: 134 start-page: 279 issue: 2–3 year: 2012 ident: 10.1016/j.schres.2017.03.040_bb0115 article-title: The MATRICS Consensus Cognitive Battery (MCCB): co-norming and standardization in Spain publication-title: Schizophr. Res. doi: 10.1016/j.schres.2011.11.026 – volume: 92 start-page: 373 issue: 2 year: 2007 ident: 10.1016/j.schres.2017.03.040_bb0055 article-title: Retesting in selection: a meta-analysis of coaching and practice effects for tests of cognitive ability publication-title: J. Appl. Psychol. doi: 10.1037/0021-9010.92.2.373 – volume: 57 start-page: 688 issue: 6 year: 2005 ident: 10.1016/j.schres.2017.03.040_bb0075 article-title: Defining a cognitive function decrement in schizophrenia publication-title: Biol. Psychiatry doi: 10.1016/j.biopsych.2005.01.003 – volume: 34 start-page: 613 issue: 4 year: 2008 ident: 10.1016/j.schres.2017.03.040_bb0005 article-title: Measurement issues in the use of cognitive neuroscience tasks in drug development for impaired cognition in schizophrenia: a report of the second consensus building conference of the CNTRICS initiative publication-title: Schizophr. Bull. doi: 10.1093/schbul/sbn037 – volume: 56 start-page: 301 issue: 5 year: 2004 ident: 10.1016/j.schres.2017.03.040_bb0045 article-title: Approaching a consensus cognitive battery for clinical trials in schizophrenia: the NIMH-MATRICS conference to select cognitive domains and test criteria publication-title: Biol. Psychiatry doi: 10.1016/j.biopsych.2004.06.023 – volume: 136 start-page: 25 issue: 1–3 year: 2012 ident: 10.1016/j.schres.2017.03.040_bb0070 article-title: Effect of the neuroprotective peptide davunetide (AL-108) on cognition and functional capacity in schizophrenia publication-title: Schizophr. Res. doi: 10.1016/j.schres.2011.11.001 – volume: 9 start-page: 419 issue: 3 year: 2003 ident: 10.1016/j.schres.2017.03.040_bb0025 article-title: The effects of practice on the cognitive test performance of neurologically normal individuals assessed at brief test-retest intervals publication-title: J. Int. Neuropsychol. Soc. doi: 10.1017/S1355617703930074 – volume: 12 start-page: 426 issue: 3 year: 1998 ident: 10.1016/j.schres.2017.03.040_bb0065 article-title: Neurocognitive deficit in schizophrenia: a quantitative review of the evidence publication-title: Neuropsychology doi: 10.1037/0894-4105.12.3.426 – volume: 125 start-page: 161 issue: 2–3 year: 2011 ident: 10.1016/j.schres.2017.03.040_bb0080 article-title: Characteristics of the MATRICS Consensus Cognitive Battery in a 29-site antipsychotic schizophrenia clinical trial publication-title: Schizophr. Res. doi: 10.1016/j.schres.2010.09.015 – volume: 165 start-page: 214 issue: 2 year: 2008 ident: 10.1016/j.schres.2017.03.040_bb0090 article-title: The MATRICS Consensus Cognitive Battery, part 2: co-norming and standardization publication-title: Am. J. Psychiatry doi: 10.1176/appi.ajp.2007.07010043 – volume: 34 start-page: 1322 issue: 5 year: 2009 ident: 10.1016/j.schres.2017.03.040_bb0095 article-title: A randomized, placebo-controlled study of memantine as adjunctive treatment in patients with schizophrenia publication-title: Neuropsychopharmacology doi: 10.1038/npp.2008.200 – volume: 24 start-page: 563 issue: 5 year: 2010 ident: 10.1016/j.schres.2017.03.040_bb0120 article-title: Influence of age on practice effects in longitudinal neurocognitive change publication-title: Neuropsychology doi: 10.1037/a0019026 |
SSID | ssj0001507 |
Score | 2.423521 |
Snippet | The MATRICS Consensus Cognitive Battery (MCCB) was developed to assess cognitive treatment effects in schizophrenia clinical trials, and is considered the FDA... Abstract The MATRICS Consensus Cognitive Battery (MCCB) was developed to assess cognitive treatment effects in schizophrenia clinical trials, and is considered... |
SourceID | proquest pubmed crossref elsevier |
SourceType | Aggregation Database Index Database Enrichment Source Publisher |
StartPage | 172 |
SubjectTerms | Adult Age Factors Cognition Computer Simulation Female Humans Male MATRICS Consensus Cognitive Battery Neuropsychological Tests Psychiatry Psychometrics Regression Analysis Reproducibility of Results Schizophrenia Schizophrenia - diagnosis Schizophrenic Psychology Sex Factors |
Title | Psychometric characteristics of the MATRICS Consensus Cognitive Battery in a large pooled cohort of stable schizophrenia patients |
URI | https://www.clinicalkey.com/#!/content/1-s2.0-S0920996417301809 https://www.clinicalkey.es/playcontent/1-s2.0-S0920996417301809 https://dx.doi.org/10.1016/j.schres.2017.03.040 https://www.ncbi.nlm.nih.gov/pubmed/28433500 https://www.proquest.com/docview/1891454909 |
Volume | 190 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1LT8MwDI4QXLggEO-XgsS1rF3SpD1OE9MGggMPiVuUpIk0NDpEx4ELEv8cu015CBCI2zrVzVo79ufus03IodFO-FzqSPiuiMDh2SgX0kRaFsw5jBgWX-ifnYvhNT-5SW_mSL-thUFaZfD9jU-vvXX4phOeZud-PO5cxjmWfQqeoJFmdREf5xKt_Oj5neaBgKfutwdpEp7dls_VHC9IICGpRYKXrFud4iuQ78PTT_CzDkODZbIU8CPtNT9xhcy5cpW8NG7sDqdjWWo_92CmU08B5dGz3tXFqH9JcUQnzreo4FOgDtGmy-YTHZdU0wmSwynO3nIFxQG6DzO8BsBIM3G0-sjSo6Eta7VGrgfHV_1hFGYrRJbLeBZlRjIuu9znuYOgnibaeC0kB9UZnWD1qS1sEXOfJDrlwjOvGdNdU4gk845Jtk7my2npNgnVBQhzy42DbDETIgOIlxcMoJ-QPrZui7D2kSobGo_j_IuJahlmt6pRhEJFqJgpUMQWid6k7pvGG7-cn7baUm1RKbhBBZHhFzn5nZyrwl6uVKKqrorVF3v7KPnJZP-w5kFrTgp2M_5Fo0s3fYS1sjzhkLLj1TcaO3u7ewASjKVxvP3vdXfIIh41bJxdMj97eHR7gKlmZr_eNPtkoTc6HZ6_AugCIno |
linkProvider | Elsevier |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1NT-MwELUqOMBlBVqWr4U10l5Dk9qxkyOqQGWX9gBF4mbZji11VVJEyoELEv98ZxIHWi0ItLcqzcRNZjzzJn0zQ8hPo53wudSR8D0RgcOzUS6kibQsmHMYMSy-0B-OxOCa_7pJbzqk39bCIK0y-P7Gp9feOhzphqfZvZtMuldxjmWfgidopBkW8a1y2L44xuD46ZXngYinbrgHeRKe3tbP1SQvyCAhq0WGl6x7neI7kLfj03v4s45DZxvkSwCQ9KT5jZuk48qv5LnxY7c4HstSu9yEmc48BZhHhyfjy_P-FcUZnTjgooJPgTtEmzabj3RSUk2nyA6nOHzLFRQn6N7P8RqAI83U0WqRpkdDX9Zqi1yfnY77gygMV4gsl_E8yoxkXPa4z3MHUT1NtPFaSA66MzrB8lNb2CLmPkl0yoVnXjOme6YQSeYdk-wbWSlnpdshVBcgzC03DtLFTIgMMF5eMMB-QvrYul3C2keqbOg8jgMwpqqlmP1RjSIUKkLFTIEidkn0InXXdN744Py01ZZqq0rBDyoIDR_IybfkXBU2c6USVfVUrP4xuEXJJZv9xJpHrTkp2M74H40u3ewB1sryhEPOjlffbuzs5e4BSTCWxvHef6_7g6wNxsMLdXE--r1P1vGbhprznazM7x_cAQCsuTmsN9BfT9AkCA |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Psychometric+characteristics+of+the+MATRICS+Consensus+Cognitive+Battery+in+a+large+pooled+cohort+of+stable+schizophrenia+patients&rft.jtitle=Schizophrenia+research&rft.au=Georgiades%2C+Anastasia&rft.au=Davis%2C+Vicki+G&rft.au=Atkins%2C+Alexandra+S&rft.au=Khan%2C+Anzalee&rft.date=2017-12-01&rft.issn=0920-9964&rft_id=info:doi/10.1016%2Fj.schres.2017.03.040&rft.externalDBID=ECK1-s2.0-S0920996417301809&rft.externalDocID=1_s2_0_S0920996417301809 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0920-9964&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0920-9964&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0920-9964&client=summon |